Newsroom

LOTTE BIOLOGICS (CEO James Park) on March 13th that it has signed a Memorandum of Understanding (MOU) with Asimov, a company headquartered in Boston, Massachusetts, to collaborate in the Contract Development and Manufacturing Organization (CDMO) business.

Through this agreement, LOTTE BIOLOGICS plans to leverage Asimov’s next-generation cell line development platform technology to provide end-to-end services, covering the entire process from cell line development to GMP manufacturing. This collaboration is expected to further strengthen LOTTE BIOLOGICS’ CDMO capabilities and track record.

LOTTE BIOLOGICS has successfully completed prior validation of the scalability and large-scale production capabilities of Asimov’s proprietary CHO Edge cell line development platform through pilot testing at its Syracuse Bio Campus. Building on these results, this agreement marks the beginning of full-scale collaboration to provide end-to-end services for customers.

Asimov’s CHO Edge system is a synthetic biology-based cell line development platform that accelerates the production of antibodies and protein therapeutics through genetic design and optimization of CHO (Chinese Hamster Ovary) cells. In particular, by incorporating process automation and AI-driven analysis, the platform enables the rapid development of customized cell lines with high productivity and consistency.

The integration of the CHO Edge system with LOTTE BIOLOGICS’ GMP manufacturing capabilities enables a seamless transition from cell line development to commercial production. This collaboration serves as a pivotal milestone, driving both the expansion of LOTTE BIOLOGICS’ CDMO business and the growth of Asimov’s operational reach.

This partnership agreement is also expected to maximize the advantages of LOTTE BIOLOGICS’ U.S.-based manufacturing facility, recently garnering significant attention.

James Park, CEO of LOTTE BIOLOGICS, expressed his optimism about the partnership, stating, “We believe this agreement will unlock the full potential of both companies’ strengths. By combining Asimov’s cutting-edge technology with LOTTE BIOLOGICS’ manufacturing excellence, we will not only deliver unparalleled services to our customers but also drive innovation in the biopharmaceutical industry. Ultimately, our goal is to make a meaningful impact on patients’ lives, and we will continue striving to be a company that contributes to a healthier future for all.”

Alec Nielsen, Co-founder and CEO of Asimov, expressed his enthusiasm, stating, “We are thrilled to see the CHO Edge system seamlessly integrated with LOTTE BIOLOGICS’ robust manufacturing capabilities. This collaboration will enable customers to transition more smoothly from cell line development to large-scale production, significantly accelerating development timelines and bringing innovations to market faster.”